Your institution may have access to this item. Find your institution then sign in to continue.
Title
Once-yearly diabetes drug.
Abstract
The article reports on results of phase 3 clinical trials of for Intarcia Therapeutics' ITCA 650, a once-a-year glucagon-like peptide-1 (GLP-1) treatment for diabetes type 2 as and comments on the pharmaceutical firms Sanofi and Medtronic's alliance for producing diabetes treatment.